These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17111156)

  • 1. Efficacy of Yasmin in premenstrual symptoms.
    Taneepanichskul S; Jaisamrarn U; Phupong V
    Arch Gynecol Obstet; 2007 Jun; 275(6):433-8. PubMed ID: 17111156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
    Sangthawan M; Taneepanichskul S
    Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of a new oral contraceptive with drospirenone on lipid metabolism.
    Taneepanichskul S; Phupong V
    Gynecol Endocrinol; 2007 Jun; 23(6):347-50. PubMed ID: 17616860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a new oral contraceptive with drospirenone on vital signs, complete blood count, glucose, electrolytes, renal, and liver function.
    Taneepanichskul S; Jaisamrarn U; Phupong V
    J Med Assoc Thai; 2007 Mar; 90(3):426-31. PubMed ID: 17427515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
    Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
    Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
    Coffee AL; Kuehl TJ; Sulak PJ
    Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
    Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
    Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
    J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
    Coffee AL; Kuehl TJ; Willis S; Sulak PJ
    Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Niknian M; Shulman LP; Lynen R
    Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.